Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $137.0 million.

  • Zevra Therapeutics' Total Liabilities rose 1245.68% to $137.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.0 million, marking a year-over-year increase of 1245.68%. This contributed to the annual value of $138.5 million for FY2024, which is 2534.6% up from last year.
  • Per Zevra Therapeutics' latest filing, its Total Liabilities stood at $137.0 million for Q3 2025, which was up 1245.68% from $139.0 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Total Liabilities high stood at $139.0 million for Q2 2025, and its period low was $5.4 million during Q3 2021.
  • Over the past 5 years, Zevra Therapeutics' median Total Liabilities value was $47.3 million (recorded in 2023), while the average stood at $69.7 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first crashed by 9258.95% in 2021, then surged by 67201.32% in 2022.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Total Liabilities stood at $5.8 million in 2021, then surged by 590.71% to $40.2 million in 2022, then surged by 174.65% to $110.5 million in 2023, then rose by 25.35% to $138.5 million in 2024, then fell by 1.09% to $137.0 million in 2025.
  • Its Total Liabilities was $137.0 million in Q3 2025, compared to $139.0 million in Q2 2025 and $131.7 million in Q1 2025.